These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 1315160)

  • 41. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo.
    Huppert M; Pappagianis D; Sun SH; Gleason-Jordan I; Collins MS; Vukovich KR
    Antimicrob Agents Chemother; 1976 Mar; 9(3):406-13. PubMed ID: 1259400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice.
    Kamberi P; Atsuro H; Takayoshi T; Masaru N
    Chemotherapy; 1998; 44(1):55-62. PubMed ID: 9444410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluconazole: a new triazole antifungal agent.
    Pasko MT; Piscitelli SC; Van Slooten AD
    DICP; 1990 Sep; 24(9):860-7. PubMed ID: 2260347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A preliminary study of in vitro antibiotic activity of saperconazole and other azoles on Paracoccidioides brasiliensis.
    San-Blas G; Calcagno AM; San-Blas F
    J Med Vet Mycol; 1993; 31(2):169-74. PubMed ID: 8389848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo activities of ketoconazole and itraconazole against Pityrosporum orbiculare.
    Faergemann J
    Antimicrob Agents Chemother; 1984 Nov; 26(5):773-4. PubMed ID: 6097177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Itraconazole and fluconazole: new drugs for deep fungal infection.
    Warnock DW
    J Antimicrob Chemother; 1989 Sep; 24(3):275-7. PubMed ID: 2553654
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro susceptibility of Malassezia furfur against azole compounds.
    Schmidt A; Rühl-Hörster B
    Mycoses; 1996; 39(7-8):309-12. PubMed ID: 9009652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole.
    Vuddhakul V; Mai GT; McCormack JG; Seow WK; Thong YH
    Int J Immunopharmacol; 1990; 12(6):639-45. PubMed ID: 2177039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro antifungal activity of azoles and amphotericin B against Malassezia furfur by the CLSI M27-A3 microdilution and Etest
    Galvis-Marín JC; Rodríguez-Bocanegra MX; Pulido-Villamarín ADP; Castañeda-Salazar R; Celis-Ramírez AM; Linares-Linares MY
    Rev Iberoam Micol; 2017; 34(2):89-93. PubMed ID: 28214276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An azole-resistant isolate of Malassezia pachydermatis.
    Nijima M; Kano R; Nagata M; Hasegawa A; Kamata H
    Vet Microbiol; 2011 Apr; 149(1-2):288-90. PubMed ID: 21074337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcription factor ADS-4 regulates adaptive responses and resistance to antifungal azole stress.
    Wang K; Zhang Z; Chen X; Sun X; Jin C; Liu H; Li S
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5396-404. PubMed ID: 26100701
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of drug and food interactions with azole antifungal agents in transplant recipients.
    Dodds-Ashley E
    Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions.
    Yu DT; Peterson JF; Seger DL; Gerth WC; Bates DW
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):755-67. PubMed ID: 15654717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-azole-resistant strain of Malassezia pachydermatis isolated from a canine Malassezia dermatitis.
    Kano R; Yokoi S; Kariya N; Oshimo K; Kamata H
    Med Mycol; 2019 Apr; 57(3):346-350. PubMed ID: 29800467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The activity of systemic antimycotic drug combinations].
    Viudes A; Pemán J; Cantón E; López-Ribot J; Gobernado M
    Rev Esp Quimioter; 2001 Mar; 14(1):30-9. PubMed ID: 11376347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Importance of the new triazoles in antifungal therapy].
    Durmaz B
    Mikrobiyol Bul; 1991 Jan; 25(1):118-23. PubMed ID: 1652677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of ketoconazole and itraconazole on growth and sterol synthesis in Pityrosporum ovale.
    Marichal P; Gorrens J; Van Cutsem J; Van Gerven F; Vanden Bossche H
    J Med Vet Mycol; 1986 Dec; 24(6):487-9. PubMed ID: 3033190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses].
    Uchida K; Matsuzaka A; Aoki K; Yamaguchi H
    Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in the treatment of systemic fungal infections.
    Walsh TJ
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.